Physician profile
Saied Jamshidi
NPI 1578648002
$5,227.19
in general payments reported to CMS, 2019-2025
34 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $506 · 2021: $1,010 · 2022: $1,777 · 2023: $807 · 2024: $606 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $779.72 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $701.97 | 2021-2025 | |
| Surgentec | $642.77 | 2022 | |
| Vivus LLC | $360.88 | 2021-2023 | Qsymia |
| Astrazeneca Pharmaceuticals LP | $344.01 | 2021-2024 | Farxiga |
| Allergan, INC. | $332.84 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $287.84 | 2019-2022 | |
| Pfizer INC. | $182.06 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $175.42 | 2020-2022 | |
| Biogen, INC. | $161.21 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $160.36 | 2022-2024 | Austedo Xr, Ajovy, Austedo |
| Amgen INC. | $118.25 | 2019-2023 | Evenity, Prolia |
| Ucb, INC. | $111.45 | 2023-2024 | Briviact, Nayzilam |
| Sk Life Science, INC. | $96.46 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.76 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $80.25 | 2021-2022 | |
| Eisai INC. | $75.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $55.78 | 2023-2024 | Aptiom |
| Argenx US, INC. | $55.76 | 2022-2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $55.23 | 2021 | |
| Neurocrine Biosciences, INC. | $45.44 | 2022-2024 | Ingrezza |
| Radius Health, INC. | $39.93 | 2019-2020 | |
| Bausch Health US, LLC | $31.25 | 2023-2025 | Aplenzin, Wellbutrin |
| Ironwood Pharmaceuticals, INC | $28.34 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.48 | 2019 | |
| Boston Scientific Corporation | $22.60 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $22.37 | 2023 | Fycompa |
| Aimmune Therapeutics, INC. | $17.99 | 2025 | Zenpep |
| Centinel Spine, LLC | $16.87 | 2021 | |
| Melinta Therapeutics, LLC | $16.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.63 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.75 | 2022 | |
| Janssen Biotech, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saied Jamshidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.